Results 131 to 140 of about 27,323 (260)

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma. [PDF]

Blood Cancer J
Sharp J, Bhatta S, Huang JJ, Thomas CJ, Elghawy O, Fitzgerald L, Reef D, Teferra A, Voorhees TJ, Gupta S, Grover NS, Barta SK, Shadman M, Epperla N.   +13 more
europepmc   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps. [PDF]

Front Oncol
Shao W, Liu Y, Huang L, Lu S, Zhai Y, Xiong Y, Chen N, Ye P, Lv Q.   +8 more
europepmc   +1 more source

Bridging Randomized Trial Efficacy and Real‐World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real‐World Evidence for Individualized Care

European Journal of Haematology, EarlyView.
ABSTRACT Multiple myeloma (MM) is predominantly a disease of older adults, yet the randomized clinical trials (RCTs) that define standards of care are conducted largely in younger, fitter, and less comorbid populations. This creates a systematic mismatch between the populations generating evidence and those receiving treatment in routine practice ...
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Santino Caserta, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma. [PDF]

Blood Adv
Iacoboni G, Kyvsgaard ER, Navarro Garcés V, Russler-Germain DA, Lewis K, Martín García-Sancho A, Carro I, Thompson PA, Therwhanger D, Quintela D, Ku M, Gómez P, Valencia E, Vega G, Jiménez-Ubieto A, Bastos-Oreiro M, Serna A, Husby S, De La Cruz B, Luan J, Camarillas S, Medina L, Cabero A, Córdoba R, Canales M, Sancho JM, Bosch F, Sureda A, Schuster S, Cheah CY, Hutchings M, Barba P, Abrisqueta P.   +32 more
europepmc   +1 more source

SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver

European Journal of Haematology, EarlyView.
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera, Izabela Cymer, John Quinn, Phillip T. Murphy, Patrick Thornton, Niamh McAuley, Harmony Black, Omar Abdelzaher, Catherine Duane, Tatiana Cichocka, Eva Szegezdi, Meegahage Perera, Gerard M. Crotty, Michelle Connolly, Aileen Walsh, Ruth Clifford, Janusz Krawczyk, Teresa Meenaghan, Vitaliy Mykytiv, Ezzat Elhassadi, Mark Coyne, Robert J. Cummins, Rowan Kuiper, Michael O'Dwyer, Siobhan V. Glavey   +24 more
wiley   +1 more source

B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer. [PDF]

Immunotargets Ther
Kielbik A, Bahlinger V, Schürch CM, Barcena ML, Vakhrusheva O, Thomas A, Tsaur I, Heitmann JS, Salih HR, Hagelstein I.   +9 more
europepmc   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

The FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta   +3 more
wiley   +1 more source

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors. [PDF]

J Immunother Cancer
Rohrberg KS, Melero I, F Sanmamed M, Muñoz-Couselo E, Cervantes A, Gambardella V, Greillier L, Garrido P, Kim HR, Lee DH, Italiano A, Cassier PA, Hiret S, Deva S, Kim TM, Blumenschein GR, Løvendahl Eefsen R, Henick BS, Perro M, Umaña P, Peixoto A, Lauener L, Weber P, Seeber S, Klein C, Higgins B, Guidi M, Kraus D, Mücke M, Heichinger C, Tran VL, Schmid D, Michielin F, Liu T, McIntyre C, Kao H, Codarri Deak L, Markert C, Moreno V.   +38 more
europepmc   +1 more source